193 related articles for article (PubMed ID: 17706503)
21. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
22. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
[TBL] [Abstract][Full Text] [Related]
23. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
24. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
25. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
26. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
27. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
30. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
[TBL] [Abstract][Full Text] [Related]
31. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
32. Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-Vbeta usage both in vivo and in vitro.
Laurin D; Spierings E; van der Veken LT; Hamrouni A; Falkenburg JH; Souillet G; Vermeulen C; Farre A; Galambrun C; Rigal D; Bertrand Y; Goulmy E; Eljaafari A
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1114-24. PubMed ID: 17085304
[TBL] [Abstract][Full Text] [Related]
33. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
35. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
[TBL] [Abstract][Full Text] [Related]
36. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
37. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
38. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
39. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
Koide T; Iinuma H; Fukushima R
Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
[TBL] [Abstract][Full Text] [Related]
40. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
